<DOC>
	<DOCNO>NCT03087760</DOCNO>
	<brief_summary>The main purpose study assess safety , tolerability anti-tumor activity experimental study drug pembrolizumab ( also know Keytruda MK-3475 ) people non-small cell lung cancer ( NSCLC ) come back radiation therapy .</brief_summary>
	<brief_title>Trial Consolidation Pembrolizumab After Concurrent Chemotherapy Proton Reirradiation Thoracic Recurrences Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC receive previous intrathoracic radiation therapy definitive intent tumor recurrence near prior irradiation field . Rebiopsy recurrence require left discretion treat physician , although every effort make confirm recurrence pathologically . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Age 18 great Patients prior invasive malignancy allow , provide treat definitive intent evidence active disease require treatment past 2 year . Patients must capable give informed consent willing able comply schedule . Serum total bilirubin ≤ 1.5 X upper limit normal ( ULN ) OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN . Platelets &gt; 100,000 cells/mm3 ANC &gt; 1,250 cells/mm3 Creatinine ≤ 1.5 X ULN OR measure calculated creatinine clearance ≥50 mL/min subject creatinine level &gt; 1.5 X institutional ULN . ( GFR also use place creatinine CrCl ) . Clinical target volume ( CTV ) size must &lt; 250 cc , 74 Gy prior radiation 2 Gy fraction previously administer . Allergy Pembrolizumab related compound History symptomatic CTCAEv4 grade ≥3 pneumonitis follow initial course definitive radiation therapy History symptomatic idiopathic pulmonary fibrosis interstitial lung disease Use continuous oxygen Diagnosis immunodeficiency exposure systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . ( Nasal oral inhaler permissible ) . Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy exception rule . Subjects require intermittent use bronchodilator local steroid injection exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . History allogenic tissue solid organ transplant Progression prior therapy antiprogrammed cell death ( PD ) 1 , antiPDL1 , antiPDL2 , antitumor necrosis factor CD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Patients know extrathoracic metastasis , include brain metastasis , know malignant pleural pericardial effusion Prior radiation treatment le 6 month plan start reirradiation part intend treatment volume Pregnant breastfeeding patient . Men woman reproductive potential may participate study unless agree use effective contraceptive method study . Known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Known active Hepatitis B ( e.g. , HBsAg positive HBV DNA detectable ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>